Literature DB >> 3038306

Effect of recombinant monokines, lymphokines, and other agents on clonal proliferation of human lung cancer cell lines.

M Munker, R Munker, R E Saxton, H P Koeffler.   

Abstract

The modulation of clonal growth of cells of 15 human lung cancer lines was examined by coculture with different recombinant lymphokines, monokines, and several agents which induce differentiation in other malignant cell systems. Recombinant human tumor necrosis factor alpha (TNF) was inhibitory to all non-small cell lung cancer cell lines with a 50% effective dose of clonal inhibition (ED50) in the range of 30-2000 units/ml. Two representative squamous lines (SK-MES and P3) had 150 to 250 high affinity (Kd approximately equal to pM) cell surface TNF receptors. In contrast, clonal growth of small cell lung cancer lines was not inhibited by TNF, and two representative lines (H69c and R592) expressed negligible cell surface TNF receptors. Recombinant alpha, beta, and gamma interferons (4000 units/ml) each inhibited greater than or equal to 30% clonal growth of more than 50% of the non-small cell lung cancer lines. TNF (100-1000 units/ml) in combination with gamma-interferon was synergistic in the inhibition of clonal growth of these cells. Further studies showed that synergism of clonal inhibition occurred even when the cells were initially exposed to gamma-interferon, washed, and plated in soft agar with TNF. All-trans-retinoic acid (ED50, 5 X 10(-7)-10(-6) M), dimethyl sulfoxide (ED50, 1.2-1.6%), and 12-O-tetradecanoylphorbol-13-acetate (ED50, 5 X 10(-8)-10(-10) M) inhibited clonal proliferation of 7 of 9, 7 of 9, and 8 of 9 non-small cell lung cancer lines, respectively. In contrast, clonal proliferation of cells of small cell lung cancer lines was decreased only slightly at almost all concentrations of each of the agents. Interleukin-1 and -2 and granulocyte-monocyte colony-stimulating factor had no effect on the clonal growth of any of the lung cancer lines. Our results suggest that TNF in combination with gamma-interferon may be therapeutically active for some patients with non-small cell lung cancer, but small cell lung cancer probably will be unresponsive to all the agents that we examined.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3038306

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Epigenetic priming of non-small cell lung cancer cell lines to the antiproliferative and differentiating effects of all-trans retinoic acid.

Authors:  Gabriele Greve; Insa Schiffmann; Michael Lübbert
Journal:  J Cancer Res Clin Oncol       Date:  2015-05-26       Impact factor: 4.553

2.  A phase II trial of a differentiating agent (tRA) with cisplatin-VP 16 chemotherapy in advanced non-small cell lung cancer.

Authors:  R Thiruvengadam; J O Atiba; S H Azawi
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

3.  An Eastern Cooperative Oncology Group phase I trial of all-trans-retinoic acid and interferon-alpha: E2Y92.

Authors:  J H Schiller; D Neuberg; D Burns; P Ritch; M Larson; M Levitt; J Dutcher
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

4.  Tumor necrosis factor: recent advances.

Authors:  R Munker; H P Koeffler
Journal:  Klin Wochenschr       Date:  1987-04-15

5.  Serum concentrations of cytokines and lung cancer survival in African Americans and Caucasians.

Authors:  Lindsey Enewold; Leah E Mechanic; Elise D Bowman; Yun-Ling Zheng; Zhipeng Yu; Glenwood Trivers; Anthony J Alberg; Curtis C Harris
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-01       Impact factor: 4.254

Review 6.  Clinical applications of recombinant human colony-stimulating factors.

Authors:  H G Klingemann
Journal:  CMAJ       Date:  1989-01-15       Impact factor: 8.262

7.  Effects of interferon alfa and gamma on human uveal melanoma cells in vitro.

Authors:  I de Waard-Siebinga; W M Creyghton; J Kool; M J Jager
Journal:  Br J Ophthalmol       Date:  1995-09       Impact factor: 4.638

8.  Characterisation and properties of a small cell lung cancer cell line and xenograft WX322 with marked sensitivity to alpha-interferon.

Authors:  S P Langdon; G J Rabiasz; L Anderson; A A Ritchie; R J Fergusson; F G Hay; E P Miller; P Mullen; J Plumb; W R Miller
Journal:  Br J Cancer       Date:  1991-06       Impact factor: 7.640

9.  Tumour necrosis factor-alpha and transforming growth factor-beta are significantly associated with better prognosis in non-small cell lung carcinoma: putative relation with BCL-2-mediated neovascularization.

Authors:  L Boldrini; A Calcinai; E Samaritani; F Pistolesi; A Mussi; M Lucchi; C A Angeletti; F Basolo; G Fontanini
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640

10.  Production of tumor necrosis factor-alpha by alveolar macrophages of lung cancer patients.

Authors:  A Okubo; S Sone; S M Singh; T Ogura
Journal:  Jpn J Cancer Res       Date:  1990-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.